Publications by authors named "Sandra Robrecht"

Claim this Profile
E
Efficacy of MRD-triggered anti-CD20 retreatment in patients with high-risk chronic lymphocytic leukemia: a case series.
Ellinor Goergen, Sandra Robrecht, Rudy Ligtvoet, Kirsten Fischer, Barbara Eichhorst

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.
Othman Al-Sawaf, Janina Stumpf, Can Zhang, Florian Simon, Francesc Bosch, Sandra Robrecht

N Engl J Med· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Perforin 1 A91V germline background in patients with aggressive B-NHL treated with R-CHOP.
Onur Cetin, Igor Age Kos, Evi Regitz, Moritz Bewarder, Torben Millard Rixecker, Sandra Robrecht

Blood Adv· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL.
Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia von Tresckow

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trial.
Florian Simon, Rudy Ligtvoet, Jan-Paul Bohn, Thomas Nösslinger, Julia von Tresckow, Sandra Robrecht

Blood· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcomes of chemoimmunotherapy with obinutuzumab/chlorambucil in chronic lymphocytic leukemia.
Valentin Goede, Kirsten Fischer, Sandra Robrecht, Adam Giza, Martin J S Dyer

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trial.
Moritz Fürstenau, Sandra Robrecht, Christof Schneider, Eugen Tausch, Adam Giza

Blood· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia.
Florian Simon, Rudy Ligtvoet, Sandra Robrecht, Paula Cramer, Nadine Kutsch

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
Petra Langerbeins, Sandra Robrecht, Pascal Nieper, Paula Cramer, Moritz Fürstenau

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study.
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang

Blood· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Nadine Kutsch, Adam Giza, Sandra Robrecht, Janina Stumpf, Anno Federhen

Eur J Haematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow

Am J Hematol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Moritz Fürstenau, Adam Giza, Jonathan Weiss, Fanni Kleinert, Sandra Robrecht

Blood· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of trephine bone marrow biopsies in the era of measurable residual diseaseResults from the CLL10 trial of the German CLL Study Group (GCLLSG).
Nadine Kutsch, Sandra Robrecht, Anna Fink, Elisabeth Lange, Rudolf Weide

Hemasphere· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Paula Cramer, Julia von Tresckow, Anna-Maria Fink, Sandra Robrecht, Adam Giza

Am J Hematol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reassessing the chronic lymphocytic leukemia International Prognostic Index in the era of targeted therapies.
Petra Langerbeins, Adam Giza, Sandra Robrecht, Paula Cramer, Julia von Tresckow

Blood· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Moritz Fürstenau, Arnon P Kater, Sandra Robrecht, Julia von Tresckow, Can Zhang

Lancet Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Sibylle C Mellinghoff, Sandra Robrecht, Rosanne Sprute, Leonie Mayer, Leonie M Weskamm

Eur J Haematol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tislelizumab plus zanubrutinib for Richter transformation: the phase 2 RT1 trial.
Othman Al-Sawaf, Rudy Ligtvoet, Sandra Robrecht, Janina Stumpf, Anna-Maria Fink

Nat Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Julia von Tresckow, Nikola Heyl, Sandra Robrecht, Adam Giza, Ali Aldaoud

Ann Hematol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi

Nat Commun· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Henriette Huber, Eugen Tausch, Christof Schneider, Simone Edenhofer, Julia von Tresckow, Sandra Robrecht

Blood· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Moritz Fürstenau, Yvonne J Thus, Sandra Robrecht, Clemens H M Mellink, Anne-Marie van der Kevie-Kersemaekers

Blood· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
Barbara Eichhorst, Carsten U Niemann, Arnon P Kater, Moritz Fürstenau, Julia von Tresckow, Sandra Robrecht

N Engl J Med· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia.
Othman Al-Sawaf, Can Zhang, Hyun Yong Jin, Sandra Robrecht, Yoonha Choi

Nat Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis